If you’re looking for a dental practice that can help you make more money, you may be interested in partnering with Large Practice Sales (LPS). LPS is a dental practice monetization company that has successfully sold practices to private equity firms and dentists of all specialties. With over 30 IDSOs in its portfolio, LPS is one of the most trusted dental monetization companies in the industry.
Unlike traditional marketing companies, LPS doesn’t charge fees from buyers or sellers. Instead, they offer you a structured partnership, allowing you to diversify your practice while still owning the practices. LPS also handles the entire process, from legal to leases to audit. In addition to helping you build a more profitable practice, LPS can guide you on how to become an effective DSO.
LPS’s partnership with dental IDSOs is a win/win situation for all parties involved. The IDSO can provide the capital necessary for the purchase of a practice, and the dentist can retain a substantial portion of the transaction value. The Dr Andreina Dulanto DDS DSO can gain valuable experience from a partner’s expert knowledge and help them grow their own practice.
LPS’s unique insider knowledge allows them to structure a partnership with a DSO that will meet both your personal and business goals. Currently, LPS is working with over 20 IDSOs in the states of Arizona, Florida, Texas, and Washington. LPS has also completed more than $500,000,000 in transactions in the last 36 months, and more than $100,000,000 in transactions in the last year for dentists under 45 years old.
LPS can increase the viability and secretion of human dental pulp stem cells. LPS activates immune cells, including T helper (Th)2 cells and inflammatory cytokines. These cytokines are important for regulating the innate and adaptive immune response.
LPS has also been shown to promote the migration and adhesion of human dental pulp stem cells. The effect of LPS was studied using primary hDPSCs and human odontoblast-like cells. After 15 days in the differentiation medium, the amount of IL-6 produced by these cells was measured. During the study, the cell survival was also assessed.
Moreover, LPS stimulated the production of BDNF in DPSCs. Compared to BM-MSCs, BDNF secretion by DPSCs was significantly higher. This was accompanied by an upregulation of osteocalcin and collagen type I. This study was conducted in a transwell cell migration assay, and qRT-PCR was used to measure the expression of MAP-kinases.
The interaction of LPS and resin monomers has also been studied in a clinical setting. In fact, LPS and resin monomers have been shown to interact and affect the regenerative functions of human dental pulp cells.
However, the role of hypoxic conditions in pulp inflammation is unclear. Hypoxia increases inflammatory responses and can lead to circulatory disturbance, while oxidative stress can interfere with the vital functions of HPCs. Therefore, it remains to be understood how LPS interacts with the resin monomers in real life.
The results indicate that the interaction of LPS and resin monomers is a clinical scenario. LPS may hinder the repair of pulp tissue in the short term, and may inhibit cytokine release from macrophages. This may lead to the development of a reduced innate immune response. This could reduce the capacity of the immune system to fight bacteria, and the development of inflammatory symptoms.